摘要
目的:探讨恩替卡韦治疗慢性乙型肝炎肝衰竭的临床效果。方法:选择笔者所在医院收治的60例慢性乙型肝炎肝衰竭患者,采用随机数字表法将其分为观察组和对照组,各30例。观察组给予恩替卡韦治疗,对照组给予拉米夫定治疗。观察治疗前后两组生化指标(白蛋白、总胆红素、丙氨酸氨基转移酶、凝血酶原活动度)的改变情况及死亡率。结果:观察组治疗3个月后死亡率为3.3%;对照组治疗3个月后死亡率为23.3%。观察组患者治疗期间死亡率低于对照组,差异有统计学意义(P<0.05)。观察组治疗后的白蛋白、总胆红素、丙氨酸氨基转移酶、凝血酶原活动度分别与对照组治疗后比较,差异有统计学意义(P<0.05)。结论:恩替卡韦治疗慢性乙型肝炎肝衰竭近期临床效果显著,值得借鉴。
Objective：To explore the short-term clinical effects of entecavir on hepatic failure in patients with chronic hepatitis B. Method：60 cases of liver failure in patients with chronic hepatitis B were selected in author’s hospital,were randomly divided into observation group and control group,30 cases in each. The observation group was given entecavir,the control group was given lamivudine. The biochemical index（albumin,total bilirubin,alanine aminotransferase, prothrombin activity） were observed before and after treatment in the two groups,the mortality rate was observed in two groups. Result：The death rate in the observation group after treatment of 3 months was 3.3%.The death rate in the control group after treatment of 3 months was 23.3%. The mortality in the observation group patients during treatmentwas lower than that in the control group,the difference was statistically significant（P〈0.05）. The albumin,total bilirubin,alanine aminotransferase,prothrombin activity in the observation group after treatment compared with those in control group after treatment,the difference was statistically significant（P〈0.05）. Conclusion：Entecavir on hepatic failure in patients with chronic hepatitis B has significant efficacy,and the therapy is worthy of reference.
出处
《中外医学研究》
2014年第18期36-38,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
